Fate Therapeutics, Inc. announced a private placement of 3,636,364 pre-funded warrants at a price of $5.499 per pre-funded warrant for gross proceeds of $19,996,365.636 on March 19, 2024. The transaction included participation from certain institutional and other accredited investors affiliated with or managed by existing investor Redmile Group, LLC. The warrants are exercisable at $0.001 exercise price per share of each pre-funded warrant.

The financing is expected to close on or about March 21, 2024, subject to customary closing conditions.